JP2005232106A - Plasma lipid inhibitor - Google Patents
Plasma lipid inhibitor Download PDFInfo
- Publication number
- JP2005232106A JP2005232106A JP2004045122A JP2004045122A JP2005232106A JP 2005232106 A JP2005232106 A JP 2005232106A JP 2004045122 A JP2004045122 A JP 2004045122A JP 2004045122 A JP2004045122 A JP 2004045122A JP 2005232106 A JP2005232106 A JP 2005232106A
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- kumazasa
- plasma
- chlorophyll
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 17
- 239000003112 inhibitor Substances 0.000 title claims abstract description 11
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 33
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229930002875 chlorophyll Natural products 0.000 claims abstract description 19
- 235000019804 chlorophyll Nutrition 0.000 claims abstract description 19
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims abstract description 19
- 241000543810 Sasa veitchii Species 0.000 claims description 34
- 239000000843 powder Substances 0.000 claims description 5
- -1 hydroxypropyl Chemical group 0.000 abstract description 4
- 229940097362 cyclodextrins Drugs 0.000 abstract description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 2
- 244000309146 drought grass Species 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 9
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 8
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 8
- 238000006116 polymerization reaction Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 3
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229930002868 chlorophyll a Natural products 0.000 description 2
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- HUKYUKIIXNZRBF-HZKYAONISA-N ε-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HUKYUKIIXNZRBF-HZKYAONISA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
この発明は、クマザサを用いた血漿脂質抑制剤に関する。 The present invention relates to a plasma lipid inhibitor using Kumazasa.
従来、クマザサを利用した健康増進剤として、特許文献１に開示されているような組成物があった。この特許文献１は、沙棘の果実を原料とする組成物に、クマザサ等を含ませたもので、摂取が容易な健康増進剤を提供するものである。
しかしながら、上記従来技術のクマザサの利用方法は、単に健康増進作用を有するものとして利用しているが、血漿脂質を抑制するものではなかった。近年、生活習慣病についての問題が多々提起され、血漿中の脂質を抑制する必要のある人が増加している。また、食生活の欧米化とともに脂肪の摂取量が増加しており、簡単に摂取可能で副作用のない血漿脂質の抑制剤が求められていた。 However, although the above-described conventional method for using Kumazasa is used merely as having a health promoting action, it does not suppress plasma lipids. In recent years, many problems related to lifestyle-related diseases have been raised, and the number of people who need to suppress plasma lipids is increasing. In addition, the intake of fat has increased with the westernization of dietary habits, and there has been a demand for a plasma lipid inhibitor that can be easily consumed and has no side effects.
この発明は上記従来の問題点に鑑みてなされたもので、容易に摂取可能であり、効果的に血漿中の脂質を抑制可能な血漿脂質抑制剤を提供することを目的とする。 The present invention has been made in view of the above-described conventional problems, and an object thereof is to provide a plasma lipid inhibitor that can be easily ingested and can effectively suppress lipids in plasma.
この発明は、クマザサの粉末から成る血漿脂質抑制剤である。またこの発明は、クマザサから抽出したクロロフィルを、シクロデキストリン又はシクロデキストリンの誘導体で包接したものである。 The present invention is a plasma lipid inhibitor made of Kumazasa powder. In the present invention, chlorophyll extracted from Kumazasa is included with cyclodextrin or a cyclodextrin derivative.
この発明の血漿脂質抑制剤は、摂取が容易で副作用がなく、効果的に血漿脂質を抑制することができるものである。 The plasma lipid inhibitor of the present invention is easy to ingest, has no side effects, and can effectively suppress plasma lipids.
以下、本発明の実施の形態を詳細に説明する。この血漿脂質抑制剤は、クマザサ粉末、または後述するように、クマザサから抽出したクロロフィルが、シクロデキストリン又はシクロデキストリンの誘導体で包接されて成るものである。 Hereinafter, embodiments of the present invention will be described in detail. This plasma lipid inhibitor is formed by inclusion of cyclodextrin or a derivative of cyclodextrin in Kumazasa powder or, as will be described later, chlorophyll extracted from Kumazasa.
クロロフィル（葉緑素）は、植物や藻類、細菌などの細胞質の葉緑体中に含まれる緑色のポリフィリン系色素であって、光合成において中心的な役割を持つマグネシウム１原子を中心に持つポリフィリンであり、多くの場合、蛋白質と複合体を作って光合成膜中に存在する。クロロフィルには、クロロフィルａ，ｂ，ｃ，ｄ，ｅ等と複数種あるが、この発明には、これらクロロフィル全般が適用可能である。 Chlorophyll (chlorophyll) is a green porphyrin pigment contained in the cytoplasmic chloroplasts of plants, algae, bacteria, etc., and is a porphyrin centered on a magnesium atom that plays a central role in photosynthesis. In many cases, it is present in the photosynthetic membrane by forming a complex with the protein. There are a plurality of chlorophylls, such as chlorophyll a, b, c, d, e, etc., but all of these chlorophylls are applicable to the present invention.
ここで、クロロフィルａの構造式を化学式１に示す。
シクロデキストリンは、デンプンから酵素反応により合成され、ブドウ糖を構成単位とする環状無還元マルトオリゴ糖である。環を構成するブドウ糖の数が、６個のもの（重合度が６のもの）をα−シクロデキストリン、７個のもの（重合度が７のもの）をβ−シクロデキストリン、８個のもの（重合度が８のもの）をγ−シクロデキストリンという。環を構成するブドウ糖の数により、環内孔のサイズが異なる。 Cyclodextrins are cyclic non-reducing maltooligosaccharides synthesized from starch by enzymatic reaction and having glucose as a structural unit. The number of glucose constituting the ring is 6 (with a degree of polymerization of 6) α-cyclodextrin, 7 (with a degree of polymerization of 7) β-cyclodextrin, 8 ( Those having a polymerization degree of 8) are called γ-cyclodextrin. The size of the inner ring hole varies depending on the number of glucose constituting the ring.
一般に市場で入手できるのはα−シクロデキストリン、β−シクロデキストリン、γ−シクロデキストリンの３種であるが、このうちγ−シクロデキストリンがクロロフィルを包接するホストとして最も適した物質であるといえる。α−シクロデキストリンの構造式を化学式２に、β−シクロデキストリンの構造式を化学式３に、γ−シクロデキストリンの構造式を化学式４に、それぞれ示す。 In general, there are three kinds of α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin available on the market. Of these, γ-cyclodextrin can be said to be the most suitable substance as a host for inclusion of chlorophyll. The structural formula of α-cyclodextrin is shown in Chemical Formula 2, the structural formula of β-cyclodextrin is shown in Chemical Formula 3, and the structural formula of γ-cyclodextrin is shown in Chemical Formula 4, respectively.
ただし、環を構成するブドウ糖の数が９個あるいは１０個、１１個、…等、さらにホストとしてのサイズが大きいシクロデキストリンを用いることで、より良好にクロロフィルを安定化することができる。したがって、γ−シクロデキストリンより更に重合度の高いシクロデキストリンが得られれば、これを本発明に用いても良い。例えば、γ−シクロデキストリンより更に重合度の高いδ−シクロデキストリン、ε−シクロデキストリンの存在が知られている。 However, chlorophyll can be stabilized more satisfactorily by using cyclodextrin having a large size as a host, such as nine, ten, eleven,..., Glucose constituting the ring. Therefore, if a cyclodextrin having a higher degree of polymerization than γ-cyclodextrin is obtained, this may be used in the present invention. For example, the presence of δ-cyclodextrin and ε-cyclodextrin having a higher degree of polymerization than γ-cyclodextrin is known.
また、シクロデキストリンの各種誘導体（例えばメチル体、ヒドロキシルプロピル体、モノアセチル体、トリアセチル体、モノクロロトリアジニル体などのシクロデキストリン各種誘導体）を、クロロフィルを包接するホストとして用いることも可能である。母体がシクロデキストリン（特にγ−シクロデキストリン）であれば、クロロフィルを安定化することができ、化学修飾の各基による影響は少ないことが知見されている。 Moreover, various derivatives of cyclodextrin (for example, various cyclodextrin derivatives such as methyl, hydroxylpropyl, monoacetyl, triacetyl, monochlorotriazinyl) can be used as a host for inclusion of chlorophyll. . It has been found that if the matrix is cyclodextrin (especially γ-cyclodextrin), chlorophyll can be stabilized and the influence of each group of chemical modification is small.
以下、クマザサから得られたクロロフィルが、シクロデキストリン又はシクロデキストリンの誘導体で包接されて成る包接化合物を、この発明では、クロロフィル−シクロデキストリン包接化合物と呼ぶ。 Hereinafter, an inclusion compound formed by inclusion of chlorophyll obtained from Kumazasa with cyclodextrin or a cyclodextrin derivative is referred to as a chlorophyll-cyclodextrin inclusion compound in the present invention.
クロロフィル−シクロデキストリン包接化合物の製造方法は、特に限定されるものではない。例えば、７５％アルコール水（即ち、７５重量％のアルコールと２５重量％の水からなる溶液）中にクロロフィルとシクロデキストリンを例えばモル比１：１で加えてよく撹拌してから、溶媒であるアルコール水を留去してクロロフィルがシクロデキストリンで包接された包接化合物を粉末として得ることができる。また、クロロフィルに対するシクロデキストリンの使用量は、特に限定されるものでないが、例えば等モル比〜１：１０モル比の範囲での使用が好適であり、等モル比〜１：２モル比の範囲での使用がより望ましい。 The method for producing the chlorophyll-cyclodextrin inclusion compound is not particularly limited. For example, chlorophyll and cyclodextrin are added in 75% alcohol water (ie, a solution consisting of 75% by weight alcohol and 25% by weight water) in a molar ratio of 1: 1, for example, and the solvent alcohol is added. The clathrate compound in which chlorophyll is clathrated with cyclodextrin by distilling off water can be obtained as a powder. Further, the amount of cyclodextrin used with respect to chlorophyll is not particularly limited. For example, it is preferably used in the range of equimolar ratio to 1:10 molar ratio, and in the range of equimolar ratio to 1: 2 molar ratio. Use in is more desirable.
次に、この発明の実施例として、クロロフィル−シクロデキストリン包接化合物の製造例、並びに実験結果について説明する。ただし、以下の実施例は、本発明を何ら限定するものではない。 Next, as examples of the present invention, production examples of chlorophyll-cyclodextrin inclusion compounds and experimental results will be described. However, the following examples do not limit the present invention.
先ず、この実施例の実験に用いたクロロフィル−シクロデキストリン包接化合物の製造例について説明する。クマザサ葉部乾重１００ｇ（湿重３６０ｇ）を５０ｍｍ幅に裁断し、このクマザサをエタノール５００ｍｌに浸して室温で２４時間放置することでクロロフィルを抽出して、クロロフィル含有エタノール溶液を得た。次いで、このクロロフィル含有エタノール溶液１００ｍｌにシクロデキストリン１ｇを加え、室温で１時間撹拌して、クロロフィル−シクロデキストリン包接化合物を含有したエタノール溶液を得た。ここで、上記の添加するシクロデキストリンとして、γ−シクロデキストリンを用いて、クロロフィル−シクロデキストリン包接化合物含有エタノール溶液を得た。 First, the manufacture example of the chlorophyll-cyclodextrin inclusion compound used for the experiment of this Example is demonstrated. Kumazasa leaf dry weight 100g (wet weight 360g) was cut to a width of 50mm, and this Kumazasa was immersed in 500ml of ethanol and allowed to stand at room temperature for 24 hours to extract chlorophyll to obtain a chlorophyll-containing ethanol solution. Next, 1 g of cyclodextrin was added to 100 ml of this chlorophyll-containing ethanol solution and stirred at room temperature for 1 hour to obtain an ethanol solution containing a chlorophyll-cyclodextrin inclusion compound. Here, γ-cyclodextrin was used as the cyclodextrin to be added to obtain an ethanol solution containing a chlorophyll-cyclodextrin inclusion compound.
このようにして得たクマザサのクロロフィル−シクロデキストリン包接化合物の粉末をマウスに与えて、血漿脂質に及ぼす影響を調べた。マウスは、１１周齢、Ｓｔｄ：ｄｄＹ、クリーンマウスのメス（ｎ＝８）を用いた。平均体重は、コントロール群が２７．９ｇ、クマザサ投与群が２８．６ｇであった。 The powder of Kumazasa chlorophyll-cyclodextrin inclusion compound thus obtained was given to mice to examine the effect on plasma lipids. As the mouse, 11 weeks old, Std: ddY, clean mouse female (n = 8) was used. The average body weight was 27.9 g in the control group and 28.6 g in the Kumazasa administration group.
使用試薬のコレステロール負荷試料は、マウス体重に対して、１４６ｍｇ／ｋｇコレステロール・３６ｍｇ／ｋｇコール酸Ｎａ・オリーブ油１８ｍｌ／ｋｇである。 The cholesterol loading sample of the reagent used is 146 mg / kg cholesterol · 36 mg / kg Na cholic acid · 18 ml / kg olive oil based on the body weight of the mouse.
試料の投与は、コントロール群には、コレステロール負荷試料と蒸留水０．５ｍｌ、クマザサ投与群は、コレステロール負荷試料とクマザサ粉末４５ｍｇ／０．５ｍｌ（１５００ｍｇ／ｋｇ）である。 The administration of the sample is a cholesterol loaded sample and 0.5 ml of distilled water in the control group, and the cholesterol loaded sample and 45 mg / 0.5 ml (1500 mg / kg) of the cholesterol loaded sample in the kumazasa administration group.
実験方法は、実験開始２４時間前からマウスを絶食させ、各群の尾採血を行った直後に、負荷試料とサンプルを経口投与した。投与後、３時間後に再度尾採血を行った。各血液を５０００ｒｐｍ３０秒で２回遠心分離して、血漿を分離した後、血漿部を２μｌずつとり、コレステロールＥ-テストワコー（総コレステロール測定用キット）、トリグリセリドＥ-テストワコー（トリグリセリド測定用キット）を用いて血漿コレステロール血漿トリグリセリド濃度を測定した。 In the experimental method, mice were fasted from 24 hours before the start of the experiment, and the loaded sample and the sample were orally administered immediately after tail blood collection of each group. After the administration, tail blood was collected again 3 hours later. Each blood was centrifuged twice at 5000 rpm for 30 seconds to separate the plasma, and then 2 μl of the plasma part was taken. Cholesterol E-Test Wako (total cholesterol measurement kit), Triglyceride E-Test Wako (Triglyceride measurement kit) Was used to measure plasma cholesterol and plasma triglyceride concentration.
測定結果を、図１〜図６に示す。図１は、クマザサ投与による血漿コレステロール濃度の変化を示す。クマザサ投与群の方がコントロール群よりもコレステロール濃度が低いことが確かめられた。図２は、クマザサ投与後３時間のコレステロール濃度変化量を示す。クマザサ投与群の方がコントロール群よりもコレステロール濃度変化量が小さいことが確かめられた。図３は、クマザサ投与による血漿コレステロール増加率を示す。クマザサ投与群の方がコントロール群よりもコレステロール増加率が低いことが確かめられた。 The measurement results are shown in FIGS. FIG. 1 shows the change in plasma cholesterol concentration by administration of Kumazasa. It was confirmed that the cholesterol concentration was lower in the Kumazasa administration group than in the control group. FIG. 2 shows changes in cholesterol concentration for 3 hours after administration of Kumazasa. It was confirmed that the Kumazasa administration group had a smaller change in cholesterol concentration than the control group. FIG. 3 shows the increase rate of plasma cholesterol by administration of Kumazasa. It was confirmed that the Kumazasa administration group had a lower cholesterol increase rate than the control group.
図４は、クマザサ投与による血漿トリグリセリド濃度の変化を示す。クマザサ投与群の方がコントロール群よりもトリグリセリド濃度が低いことが確かめられた。図５は、クマザサ投与後３時間のトリグリセリド濃度変化量を示す。クマザサ投与群の方がコントロール群よりもトリグリセリド濃度変化量が小さいことが確かめられた。図６は、クマザサ投与による血漿トリグリセリド増加率を示す。クマザサ投与群の方がコントロール群よりもトリグリセリド増加率が低いことが確かめられた。 FIG. 4 shows the change in plasma triglyceride concentration by administration of Kumazasa. It was confirmed that the triglyceride concentration was lower in the Kumazasa administration group than in the control group. FIG. 5 shows the amount of change in triglyceride concentration for 3 hours after administration of Kumazasa. It was confirmed that the amount of change in triglyceride concentration was smaller in the Kumazasa administration group than in the control group. FIG. 6 shows the increase rate of plasma triglyceride by administration of Kumazasa. It was confirmed that the triglyceride increase rate was lower in the Kumazasa administration group than in the control group.
Claims (2)
A plasma lipid inhibitor characterized in that chlorophyll extracted from Kumazasa is encapsulated with cyclodextrin or a derivative of cyclodextrin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004045122A JP2005232106A (en) | 2004-02-20 | 2004-02-20 | Plasma lipid inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004045122A JP2005232106A (en) | 2004-02-20 | 2004-02-20 | Plasma lipid inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2005232106A true JP2005232106A (en) | 2005-09-02 |
Family
ID=35015420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004045122A Pending JP2005232106A (en) | 2004-02-20 | 2004-02-20 | Plasma lipid inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2005232106A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008545779A (en) * | 2005-06-10 | 2008-12-18 | ペル−オーケ・アルベルトソン | Use of plant cell membranes for the treatment of obesity |
| JP2010037296A (en) * | 2008-08-07 | 2010-02-18 | Hakuju Life Science Co Ltd | Visceral fat accumulation inhibitor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05252898A (en) * | 1992-03-12 | 1993-10-05 | Lotte Co Ltd | Obesity-preventive food/obesity-preventive agent |
| JP2000093121A (en) * | 1998-09-18 | 2000-04-04 | Nonogawa Shoji Kk | Beauty food |
| JP2003321474A (en) * | 2002-04-30 | 2003-11-11 | Kentetsuku:Kk | Clathrate compound |
-
2004
- 2004-02-20 JP JP2004045122A patent/JP2005232106A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05252898A (en) * | 1992-03-12 | 1993-10-05 | Lotte Co Ltd | Obesity-preventive food/obesity-preventive agent |
| JP2000093121A (en) * | 1998-09-18 | 2000-04-04 | Nonogawa Shoji Kk | Beauty food |
| JP2003321474A (en) * | 2002-04-30 | 2003-11-11 | Kentetsuku:Kk | Clathrate compound |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008545779A (en) * | 2005-06-10 | 2008-12-18 | ペル−オーケ・アルベルトソン | Use of plant cell membranes for the treatment of obesity |
| JP2010037296A (en) * | 2008-08-07 | 2010-02-18 | Hakuju Life Science Co Ltd | Visceral fat accumulation inhibitor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6566886B2 (en) | Stabilized sulforaphane | |
| Fujisawa et al. | Biological and chemical stability of garlic-derived allicin | |
| EP3490575B2 (en) | Plant extract highly concentrated in safranal, production method and uses thereof | |
| US20200347153A1 (en) | Methods for forming inclusion complexes with hydrophilic beta-cyclodextrin derivatives and compositions thereof | |
| FR2918663A1 (en) | CYCLOHEXENONES OF ANTRODIA CAMPHORATA FOR THE TREATMENT OF HEPATITIS B VIRUS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| EP3454875B1 (en) | Method for producing celastrol and pentacyclic triterpene derivatives | |
| JP5144274B2 (en) | Use of lipoic acid-containing cyclodextrin complex | |
| Sørensen et al. | Growth, chemical composition, histology and antioxidant genes of Atlantic salmon (Salmo salar) fed whole or pre-processed Nannochloropsis oceanica and Tetraselmis sp. | |
| KR20210041037A (en) | Use of the curcuminoid composition | |
| JP7525473B2 (en) | Curcuminoid Composition | |
| JP2003012520A (en) | Antioxidant and food and drink containing the same | |
| JP4814524B2 (en) | Preparations that lower cholesterol | |
| JP2005232106A (en) | Plasma lipid inhibitor | |
| WO2000053637A1 (en) | INCLUSION COMPLEXES OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES WITH η-CYCLODEXTRIN | |
| JP4783512B2 (en) | A feed composition that suppresses methane production in ruminants | |
| EP3240565A1 (en) | Method for obtaining a superoxide dismutase (sod)-concentrated protein extract | |
| JP5723276B2 (en) | Cholesterol ester transfer protein inhibitor | |
| JP2011256133A (en) | Sr-b1 protein expression enhancer | |
| JP2016013981A (en) | Tubulin polymerization activity regulator, food and agent comprising the same, and method of producing tubulin polymerization activity regulator | |
| JP6948671B2 (en) | Composition for promoting fecal lipid excretion containing D-sorbose as an active ingredient | |
| JP2009196922A (en) | Sustained-release ferulic acid preparation | |
| CA2682781C (en) | Cleome spinosa extract used in pharmaceutical preparations and cosmetic compositions | |
| JP5426156B2 (en) | Defecation promoting composition | |
| JP2006089426A (en) | Composition useful for human body | |
| JP2016094378A (en) | Composition for suppressing mouth odors containing myrsine seguinii h. lev. extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100519 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100929 |